Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Steven Liu (NPI 1164462834)

Field	Value
Entity Type	Individual
Organization	Steven Liu
Address	2925 Debarr Rd
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 8, 2006

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider's visible payer footprint is effectively single-payer: total Medicare revenue is $3.4M and there is no Medicaid billing on file. The absence of Medicaid activity means the practice's revenue and contract exposure are concentrated in the Medicare channel rather than split across state Medicaid programs.

Revenue is highly concentrated in a small set of biologic and immunotherapy drugs: the precomputed top 3 Medicare codes (J9271, J9299, J9144) account for 74.4% of this provider's total Medicare revenue. Those three codes — pembrolizumab (J9271), nivolumab (J9299), and daratumumab with hyaluronidase (J9144) — dominate the revenue mix and indicate dependence on high-cost oncology infusions.

Operational profile points to an infusion-centric hematology/oncology practice: the top-revenue codes are injectable monoclonal antibodies (J9271, J9299, J9144) and the claims mix includes chemotherapy administration add-on and primary infusion codes such as 96413, 96417, 96415 and G0498. High counts of these administration codes alongside the drug codes suggest the practice runs regular outpatient infusion sessions and manages complex chemotherapy/immunotherapy regimens.

For pembrolizumab (J9271) this provider is a major national contributor: J9271 shows 35.8K claims, $1.5M revenue (44.7% of the provider's Medicare revenue) and ranks #54 of 1841 providers nationally (97th percentile; notably above typical national volume for this code). By contrast, J9299 (24.4K claims, $585.6K revenue; 78th percentile; typical, unremarkable volume for this code) and J9144 (11.5K claims, $437.8K revenue; 73th percentile; typical, unremarkable volume for this code) are more typical in their national standing, highlighting that pembrolizumab is the standout product in this clinician's mix.

The provider shows above-typical volume for several non-drug services that support active outpatient management: 99214 has 786 claims and $97.5K revenue (2.8% of Medicare revenue) and ranks #20405 of 479517 providers nationally (96th percentile; notably above typical national volume for this code), and 96413 ranks in the 95th percentile (615 claims, $71.3K revenue). These E/M and chemotherapy-administration positions indicate substantial ongoing patient management and infusion throughput, not just episodic drug dispensing.

Claim counts for leading oncology agents demonstrate scale of infusion throughput: J9271 appears with 35.8K claims, J9299 with 24.4K claims, and J9144 with 11.5K claims. Those absolute claim volumes, together with the revenue concentration in the top three codes, point to a practice model built around frequent administration of high-cost oncologic biologics.

The clinician provides a modest breadth of diagnostics and procedures but at low volumes relative to infusion activity: there are small counts for bone marrow biopsy (38222: 13 claims, $2.2K revenue), CT of the abdomen/pelvis with contrast (74177: 64 claims, $12.7K revenue), and other imaging codes. This pattern suggests most diagnostic or procedural services are either ancillary to the infusion clinic or performed elsewhere, while the primary business is drug administration.

The provider has an established billing history with an NPI enumerated 2006-06-08 (~20 years ago), which supports continuity of service and long-tenure operations in the local market. Given the strong Medicare revenue concentration and lack of Medicaid billing, analysts should view contracting or utilization shifts for the provider primarily through a Medicare-focused lens and note potential business risk from concentration around a few high-revenue immunotherapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	35,800	$40	$1.5M
J9299	Injection, nivolumab, 1 mg	24,400	$20	$585.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	11,520	$40	$437.8K
J0897	Injection, denosumab, 1 mg	12,960	$20	$246.2K
J9312	Injection, rituximab, 10 mg	2,390	$60	$153K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	790	$120	$97.5K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	900	$110	$95.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	620	$120	$71.3K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	6,300	$10	$63K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	260	$180	$46.6K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Steven Liu — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	13,300	$40	$609.5K
J9299	1	10	19,440	$20	$472.8K
J9144	1	10	10,980	$40	$408.7K
J9312	2	10	2,330	$60	$168.4K
J0897	2	30	2,700	$20	$82.7K
J9264	2	10	7,570	$10	$75.8K
Q5111	1	10	700	$110	$71.7K
96413	1	20	230	$110	$30.2K
99214	19	1,210	90	$100	$16.2K
74177	38	60	80	$110	$15.5K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Steven Liu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Max Rabinowitz	AK	Hematology & Oncology Physician	$2M	$0
Natalie Wallace	AK	Hematology & Oncology Physician	$1.2M	$0
Alaska Oncology And Hematology LLC	AK	Hematology & Oncology Physician	$0	$375.5K
Jeremy Rosiecki	AK	Physician Assistant	$97.2K	$0
Zach Zipsir	AK	Physician Assistant	$84.4K	$0

Nearby Providers

Other providers in the same ZIP code as Steven Liu, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$397.1M
Providence Health & Services Washington	AK	General Acute Care Hospital	$0	$161.5M
Southcentral Foundation	AK	Community Health Clinic/Center	$0	$130.3M
Alaska Native Tribal Health Consortium	AK	Transportation Broker	$0	$65.5M
The Arc Of Anchorage	AK	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$50.8M
Good Samaritan Care Services	AK	In Home Supportive Care Agency	$0	$46.1M
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$33.1M
Galen Hospital Alaska, Inc.	AK	General Acute Care Hospital	$0	$31.8M
Anchorage Community Mental Health	AK	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$31.7M
Patient Housing At Anmc	AK	General Acute Care Hospital	$0	$31M

Steven Liu — Billing Profile & Reimbursement Data

Sign up for Steven Liu — Billing Profile & Reimbursement Data policy alerts

Steven Liu — Billing Profile & Reimbursement Data

Sign up for Steven Liu — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References